[Federal Register Volume 71, Number 72 (Friday, April 14, 2006)]
[Notices]
[Page 19535]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-5531]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Use of Single Chain T-
Cell Receptors To Diagnose and Treat Cancer

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services (HHS), is contemplating the 
grant of an exclusive patent license to practice the inventions 
embodied in PCT Application Serial No. PCT/US04/29608, filed September 
13, 2004 [HHS Ref. No. E-106-2004/0-PCT-01], entitled ``Compositions 
Comprising T-Cell Receptors and Methods of Use Thereof,'' to Altor 
Bioscience Corporation, which is located in Miramar, Florida. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of single chain, soluble T-
Cell Receptors that recognize NY-ESO, MART-1, and gp100 for diagnosis, 
prophylaxis, and treatment of melanoma, myeloma, sarcoma, head and neck 
cancer, bladder cancer, esophageal cancer; lung cancer; stomach cancer; 
breast cancer; ovarian cancer, colorectal cancer, prostate cancer or 
liver.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before June 
13, 2006 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Michelle A. Booden, PhD., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; E-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The technology describes the composition and 
use of nucleic acid sequences that encode polypeptides capable of 
forming a T-Cell Receptor (TCR) in a genetically engineered cell. 
Specifically, these nucleic acid sequences will encode TCRs specific to 
tumor associated antigens (TAA), gp100, NY-ESO-1, and MART-1. T-Cells 
engineered with these tumor associated antigen specific TCRs show 
specific immune responses against TAA expressing cancer cells. 
Additionally, a method of treating or preventing cancer by 
administrating the above described TCRs is also disclosed.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 6, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E6-5531 Filed 4-13-06; 8:45 am]
BILLING CODE 4140-01-P